文献速递妇科

接受PARP抑制剂维持治疗的卵巢癌患者循环肿瘤DNA监测:能否进一步实现个体化治疗

Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
PubMed 文献 · Gynecol Oncol · 2025-11-17

多中心回顾性队列研究分析53例接受PARP抑制剂维持治疗的卵巢癌患者的商业ctDNA检测数据,评估ctDNA对复发/进展的预测价值。结果显示PARP抑制剂治疗期间ctDNA状态较CA-125或BRCA/HR状态更能预测疾病进展,但需进一步分析。

要点

  • PARP抑制剂治疗前58%(7/12)患者可检出ctDNA,无一例实现持续ctDNA清除。
  • 治疗前3个月内持续或转为ctDNA阳性与更短无进展生存期显著相关(p=0.01)。
  • 治疗6个月内持续ctDNA阴性或清除者较持续阳性或转阳者无进展生存期显著改善(p=0.003)。

核心结论

  • PARP抑制剂治疗期间ctDNA状态较CA-125或BRCA/HR状态更能预测疾病进展,数据提示ctDNA是治疗决策中有前景的生物标志物,但需进一步分析。

研究设计与样本

  • 多中心回顾性队列研究,使用真实世界商业ctDNA检测(Signatera™,Natera公司)数据,纳入53例对倒数第二次铂类治疗有反应后接受PARP抑制剂维持治疗的卵巢癌患者。

主要发现

  • 53例患者中,PARP抑制剂开始前样本12例,治疗前12个月内样本34例,治疗12个月后样本26例。
  • PARP抑制剂开始前58%(7/12)患者可检出ctDNA,无一例在PARP抑制剂治疗期间实现持续ctDNA清除。
  • 截至末次已知临床随访,ctDNA阴性患者无一例复发。
  • 治疗前3个月内持续或转为ctDNA阳性与无进展生存期显著缩短相关(p=0.01)。
  • 治疗6个月内持续ctDNA阴性或清除ctDNA者较持续阳性或转为阳性者无进展生存期显著改善(p=0.003)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步分析(additional analyses are warranted)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Recommendations for the length of maintenance therapy with poly (ADP-ribose) polymerase inhibitors (PARPi) in patients with ovarian cancer (OC) are derived from clinical trials with various durations of therapy. Here, we evaluated whether circulating tumor DNA (ctDNA) predicted recurrence/progression in OC patients receiving PARPi maintenance. METHODS: This was a multi-center retrospective cohort study of real-world data from commercial ctDNA testing (Signatera™, Natera, Inc.) in patients with OC on PARPi maintenance following response to penultimate platinum-based therapy. Clinical data were collected on stage, setting, pathologic subtype, and biomarker status. RESULTS: Fifty-three patients with OC were analyzed, with samples collected: i) prior to starting PARPi (pre-PARPi; N = 12), ii) during the first 12 months on PARPi (early; N = 34), and iii) beyond 12 months of PARPi therapy (late; N = 26). ctDNA was detected prior to PARPi initiation in 58 % (7/12) of patients, and none experienced sustained ctDNA clearance on PARPi therapy. Notably, none of the ctDNA-negative patients recurred at the last known clinical follow-up. Persistent/conversion to ctDNA positivity within the first 3 months of therapy was associated with significantly shorter progression-free survival (PFS) (p = 0.01). Patients who were serially ctDNA-negative/cleared ctDNA within 6 months on therapy had significantly improved PFS compared to those who were persistently positive/converted to positive (p = 0.003). Correlation with CA-125 and BRCA/HR status was not significant. CONCLUSIONS: ctDNA status on-PARPi was a stronger predictor of disease progression compared to CA-125 or BRCA/HR status. While additional analyses are warranted, our data suggest that ctDNA is a promising biomarker for therapeutic decision-making.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Toboni MD, Evans ET, Scalise CB, et al. Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment? Gynecol Oncol. 2025. PMID: 41252813. doi:10.1016/j.ygyno.2025.11.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。